Homology Medicines COO Sam Rasty stepping down
Homology Medicines announced changes to its leadership team, which positions the company for continued growth as a clinical-stage company. Sam Rasty is stepping down as COO to assume the role of president and CEO of Platelet BioGenesis, an early stage biotechnology company. In conjunction with Rasty's departure, Brad Smith, CFO, who also manages Homology's information technology, facilities and intellectual property portfolio, will assume responsibility for corporate development. Michael Blum, VP of Commercial Strategy, will lead commercial efforts and report directly to the CEO, as Homology advances lead gene therapy candidate HMI-102 through Phase 1/2 studies for adults with phenylketonuria, a rare, inborn error of metabolism caused by a mutation in the PAH gene.